Antibiotic Resistant Staphylococcus Aureus Infection, Bone and Joint Infection
Conditions
Brief summary
S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.
Interventions
OTHERRole of rifampin in staphylococcal PJI
the aim is to determine if the dose and the duration of rifampin influenced the prognosis
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Inclusion criteria
patients having had acute PJI (i.e. \<1 month following the implantation), DAIR with exchange of removal components) due to S. aureus and coagulase-negative staphylococci (2011-2016)
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| description of the use of rifampicin : rate of use | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | the aim is to determine how the use of rifampin influence the prognosis in staphylococcal acute post-operative prosthetic joint infection treated with DAIR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of failure for treatment using rifampin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin |
| rate of adverse event with rifampin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | Description of adverses events leading to stop the rifampicin |
Countries
France
Outcome results
None listed